Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Robert on Evaluating Trends in Biomarker Testing in Metastatic NSCLC

September 9th 2021

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Dr. Blakely on Utilizing Osimertinib in Resectable EGFR-Mutant NSCLC

September 9th 2021

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC

September 8th 2021

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

Selpercatinib Elicits Durable Antitumor Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Sotorasib Induces Intracranial Activity in KRAS G12C–Mutated NSCLC Brain Metastases

September 8th 2021

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma

September 8th 2021

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

September 8th 2021

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

September 8th 2021

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

September 8th 2021

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC

September 7th 2021

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

Dr. Dietrich on Future Research Directions in Lung Cancer

September 3rd 2021

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Dr. Patil on ADAURA Data with Osimertinib in NSCLC

September 2nd 2021

Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.

PACIFIC Led to Subtle but Swift Adoption of Concurrent Chemoradiation and Durvalumab in Stage III NSCLC

September 2nd 2021

An increase in the use of concurrent chemoradiation followed by durvalumab was found in patients with stage III non–small cell lung cancer who were treated at 3 Dutch centers in The Netherlands between 2015 and 2019.

Dr. Stevenson on the Importance of Early Screening in Lung Cancer

September 1st 2021

James Stevenson, MD, discusses the importance of early screening in lung cancer.

Biomarker Discovery and Testing Are Key to Improving Care for Early-Stage Resectable NSCLC

September 1st 2021

Jay M. Lee, MD, discusses the implications of the ADAURA trial in early-stage resectable NSCLC, the importance of molecular testing, and the need for a multidisciplinary approach in this population.

Checkpoint Inhibitors, Electrical Fields Provide New Options for Mesothelioma

August 31st 2021

Despite an outsized reputation fueled by late-night commercials from personal injury lawyers, mesothelioma is a rare disease with approximately 3000 new diagnoses every year in the United States.

Addition of Veliparib to Frontline Chemo Misses OS End Point in Current Smokers With Advanced Squamous NSCLC

August 31st 2021

The addition of veliparib to platinum-based chemotherapy in the frontline treatment of current smokers with advanced squamous non–small cell lung cancer did not significantly improve overall survival, but the LP52 signature may identify a subset of patients who will derive benefit from the combination.

Nivolumab and Tumor-Infiltrating Lymphocyte Regimen Elicits Activity in Metastatic NSCLC

August 27th 2021

Nivolumab followed by tumor-infiltrating lymphocyte therapy and maintenance nivolumab demonstrated a suitable safety profile and antitumor activity in patients with metastatic non–small cell lung cancer.

Dr. Patil on Key Developments With Targeted Therapy in Lung Cancer

August 26th 2021

Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.